Log In
BCIQ
Print this Print this
 

Edarbyclor, Azilsartan medoxomil/chlorthalidone

  Manage Alerts
Collapse Summary General Information
Company Takeda Pharmaceutical Co. Ltd.
DescriptionFixed-dose combination of azilsartan medoxomil, an angiotensin II type 1 (AT1) receptor blocker, and chlorthalidone, a long-acting oral thiazide-like diuretic
Molecular Target Angiotensin II type 1 (AT1) receptor (AGTR1)
Mechanism of Action 
Therapeutic ModalitySmall molecule: Combination
Latest Stage of DevelopmentMarketed
Standard IndicationHypertension
Indication DetailsTreat hypertension
Regulatory Designation
PartnerArbor Pharmaceuticals Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
Get a free BioCentury trial today